NCT04953130View on ClinicalTrials.gov

Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

10,400

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

October 31, 2026

Conditions
HPV InfectionVaccine Preventable Disease
Interventions
BIOLOGICAL

Gardasil® HPV vaccine

Single dose 4-valent HPV vaccine in males. Gardasil®, manufactured by MSD, consists of a licensed prophylactic virus-like particle (VLP) vaccine that protects against 4 HPV genotypes (HPV 6, 11, 16, 18).

Trial Locations (1)

Unknown

Mwanza Intervention Trials Unit, Mwanza

All Listed Sponsors
collaborator

Mwanza Intervention Trials Unit, National Institute for Medical Research

UNKNOWN

collaborator

York Biomedical Research Institute, Hull York Medical School, University of York

UNKNOWN

collaborator

Cancer Epidemiology Research Programme Institut Català d' Oncologia

UNKNOWN

collaborator

Karolinska Institute Department of Laboratory Medicine

UNKNOWN

collaborator

University of Cambridge

OTHER

lead

London School of Hygiene and Tropical Medicine

OTHER